Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RARE Ultragenyx Pharmaceutical Inc

休市中 01-30 16:00:00 EST

24.07

-0.20

-0.82%

盘后23.63

-0.44-1.83%

19:47 EST

最高24.59	最低23.26	成交量377.56万
今开24.13	昨收24.27	日振幅5.48%
总市值23.22亿	流通市值22.34亿	总股本9,648万
成交额8,992万	换手率4.07%	流通股本9,279万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RARE","market":"US","secType":"STK","nameCN":"Ultragenyx Pharmaceutical Inc","latestPrice":24.07,"timestamp":1769806800000,"preClose":24.27,"halted":0,"volume":3775613,"hourTrading":{"tag":"盘后","latestPrice":23.63,"preClose":24.07,"latestTime":"19:47 EST","volume":34139,"amount":820224.06,"timestamp":1769820442798,"change":-0.44,"changeRate":-0.01828,"amplitude":0.023681},"delay":0,"changeRate":-0.008240626287597828,"floatShares":92794919,"shares":96477569,"eps":-5.942723,"marketStatus":"休市中","change":-0.2,"latestTime":"01-30 16:00:00 EST","open":24.13,"high":24.59,"low":23.26,"amount":89918866.5241,"amplitude":0.0548,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.942723,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1770022800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":24.27,"preHourTrading":{"tag":"盘前","latestPrice":24.23,"preClose":24.27,"latestTime":"09:25 EST","volume":808,"amount":19715.629856,"timestamp":1769783100048,"change":-0.04,"changeRate":-0.001648,"amplitude":0.038747},"postHourTrading":{"tag":"盘后","latestPrice":23.63,"preClose":24.07,"latestTime":"19:47 EST","volume":34139,"amount":820224.06,"timestamp":1769820442798,"change":-0.44,"changeRate":-0.01828,"amplitude":0.023681},"volumeRatio":1.7669702928309303,"impliedVol":0.4592,"impliedVolPercentile":0.247},"requestUrl":"/m/hq/s/RARE","defaultTab":"news","newsList":[{"id":"1170251319","title":"Ultragenyx重新向美国FDA提交UX111基因疗法治疗A型Sanfilippo综合征的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1170251319","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170251319?lang=zh_cn&edition=full","pubTime":"2026-01-30 21:32","pubTimestamp":1769779956,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical（纳斯达克代码：RARE）已正式向美国食品药品监督管理局重新递交了UX111 AAV基因疗法的生物制品许可申请。该疗法旨在治疗A型Sanfilippo综合征（又称MPS IIIA），这是一种罕见的遗传性神经退行性疾病。\n此次重新提交基于最新临床数据对申请材料进行了全面优化，标志着该基因疗法在监管审批进程中迈出关键一步。若获批，UX111将成为全球首个针对该致命性儿童罕见病的基因治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2595749031","title":"两项三期临床折戟致股价腰斩，杰富瑞看好Ultragenyx (RARE.US)2026年借候选药物反弹，给予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2595749031","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595749031?lang=zh_cn&edition=full","pubTime":"2025-12-31 09:15","pubTimestamp":1767143744,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由于针对罕见骨病资产的两项后期临床试验失败，Ultragenyx Pharmaceutical  周一收盘下跌约 42%，但投行杰富瑞发布报告称，鉴于其管线中的其他候选药物，该公司有望在 2026 年迎来反弹。杰富瑞分析师 Maury Raycroft，给予 Ultragenyx “买入”评级并表示，公司明年可能会从 apazunersen  的三期数据公布中获益，这是一种用于治疗天使综合征的反义寡诺聚糖核酸药物。他补充称，该公司维持其 2027 年盈利指引，并将在 2026 年初明确削减开支的计划。然而，花旗对 Ultragenyx 的态度则没那么乐观。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RARE"],"gpt_icon":0},{"id":"1166494163","title":"Ultragenyx完成向美国FDA滚动提交DTX401 AAV基因疗法治疗Ia型糖原贮积症的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1166494163","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166494163?lang=zh_cn&edition=full","pubTime":"2025-12-31 05:06","pubTimestamp":1767128808,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical已顺利完成向美国食品药品监督管理局滚动提交DTX401 AAV基因疗法治疗Ia型糖原贮积症的生物制品许可申请。这一里程碑标志着该创新疗法在监管审批道路上迈出关键一步，为罕见病患者带来新的治疗希望。DTX401作为针对GSDIa的基因治疗产品，采用腺相关病毒载体技术，旨在通过单次给药实现长期疗效。若最终获批，该疗法将填补GSDIa领域精准治疗的空白，重塑罕见病治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2595715068","title":"华尔街顶级分析师最新评级：DigitalBridge遭下调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2595715068","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595715068?lang=zh_cn&edition=full","pubTime":"2025-12-31 00:09","pubTimestamp":1767110940,"startTime":"0","endTime":"0","summary":"华尔街最受热议、影响市场走势的分析师研报评级，现已汇总呈现。以下为 The Fly 整理的、投资者需重点关注的当日最新评级调仓信息。　　阿格斯投行将必和必拓评级从‘持有’上调至‘买入’，目标价定为 68 美元。　　加拿大皇家银行资本将DigitalBridge评级从‘跑赢行业’下调至‘与行业持平’，目标价从 23 美元下调至 16 美元。该行认为，公司采用成熟供应链的标准化零部件开展研发，有望大幅降低先进核反应堆开发商通常面临的监管与技术壁垒。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a9c5b2ea6477641c148f3bfa413b9f24","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-31/doc-inheqyvi5645186.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4205","LU0300736492.USD","LU2065171402.SGD","LU0963586101.USD","RARE","VRNS","BK4135","BK4160","BK4233","NKLR","MREO","BK4182","LU2125909759.SGD","LU2065170008.USD","DBRG","BK4139","LU0274383776.USD","LU2065731478.USD","BK4613","IE00BLDYK493.USD","LU0300736062.USD","BK4015","BK4532","LU2125909916.SGD","BK4588","BK4505","LU1923622291.USD","LU2286300806.USD","CVLT","LU0054578231.USD","LU2065171311.SGD","RBRK","BK4097","IE00B64QTZ34.USD","LU2065169927.USD","BHP","BK4585","ERO","BK4168"],"gpt_icon":0},{"id":"1147466746","title":"Ultragenyx Pharmaceutical暴跌，遗传性骨病在研药物临床试验失败","url":"https://stock-news.laohu8.com/highlight/detail?id=1147466746","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147466746?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:49","pubTimestamp":1767019741,"startTime":"0","endTime":"0","summary":"在后期临床试验中未达到主要疗效终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3582e8b9661b08b591794cc3daf7054b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1386812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Ultragenyx Pharmaceutical暴跌，遗传性骨病在研药物临床试验失败","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["RARE"],"gpt_icon":0},{"id":"2595352767","title":"美股异动 | 治疗遗传性骨病在研药物临床试验失败 Ultragenyx Pharmaceutical(RARE.US)盘前暴跌超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595352767","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595352767?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:23","pubTimestamp":1767018233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周一美股盘前，Ultragenyx Pharmaceutical(RARE.US)股价暴跌，截至发稿，该股跌超42%，报19.69美元。消息面上，该公司宣布，其一款治疗特定遗传性骨病的在研药物，在后期临床试验中未达到主要疗效终点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"3582e8b9661b08b591794cc3daf7054b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386812.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1128746412","title":"Ultragenyx公布Setrusumab（Ux143）治疗成骨不全症的三期Orbit及Cosmic研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1128746412","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128746412?lang=zh_cn&edition=full","pubTime":"2025-12-29 21:32","pubTimestamp":1767015148,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc宣布，其针对成骨不全症开发的药物Setrusumab（研发代号Ux143）在三期临床试验Orbit与Cosmic中取得积极结果。这两项研究旨在评估该药物对患者骨骼强度与骨折风险的改善效果，初步数据表明其在主要终点上表现出显著疗效。公司计划基于现有结果与监管机构进一步沟通，推进后续申报流程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1163752901","title":"“圣诞节可以收礼12天”？2026年这12只股票可作节日佳礼","url":"https://stock-news.laohu8.com/highlight/detail?id=1163752901","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163752901?lang=zh_cn&edition=full","pubTime":"2025-12-25 15:29","pubTimestamp":1766647746,"startTime":"0","endTime":"0","summary":"特斯拉被认为是“美股七巨头”中最“顽皮”的一只股票，仅有45%的分析师给予其“买入”评级，且平均目标价低于当前股价。相比之下，罗素1000指数成分股的平均“买入”评级比例目前约为58%。大型成长股大幅上涨，就像拆开一份期盼已久的圣诞礼物。在罗素1000指数中，只有大约5%的股票，其目标价明显低于当前交易价格。即便是逆向投资者，可能也未必认为这是一份最好的“礼物”。","market":"us","thumbnail":"https://community-static.tradeup.com/news/1303599391ea8a5a388ca86bb9de75b3","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/1303599391ea8a5a388ca86bb9de75b3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"13d44e8d649e7e968597cd411f47871e","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FRMI","Q","ALK","TSLA","MSFT","AUR","LOAR","AMZN","NVDA","RARE","VKTX","MSTR","QXO"],"gpt_icon":1},{"id":"2589828371","title":"数据：RARE 2小时小涨超 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828371","media":"链捕手","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589828371?lang=zh_cn&edition=full","pubTime":"2025-12-06 17:30","pubTimestamp":1765013429,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据币安现货数据显示，市场出现大幅波动。RARE 2小时涨幅达 11.32%。此外，ARDR 触及今日新低，跌幅为 7.15%；EGLD、LSK、PYR、CYBER、RED、RESOLV 和 WAL 均出现“冲高回落”状态，跌幅分别为 6.82%、5.29%、6.57%、5.41%、8.38% 和 6.81%。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2226873","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2584590909","title":"数据：多个代币出现冲高回落，RARE 跌超 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584590909","media":"链捕手","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584590909?lang=zh_cn&edition=full","pubTime":"2025-11-20 11:30","pubTimestamp":1763609434,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据币安现货数据显示，市场出现多种动态。CHR 涨幅为 6.92%，同时触及探底回升状态，ONE 涨幅为 6.49%，同样触及探底回升状态。另一方面，FET 出现“冲高回落”状态，跌幅为 5.7%。FIS、ILV 和 RARE 也分别出现“冲高回落”状态，跌幅为 10.61%、10.53% 和 12.83%。PYR 的跌幅更是达到 23.99%。 ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2222062","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1113313764","title":"异动解读 | Ultragenyx盘中大跌11.89%，4亿美元出售Crysvita特许权使用费引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1113313764","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113313764?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:43","pubTimestamp":1762353801,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc今日盘中大跌11.89%，引发市场广泛关注。这一显著跌幅主要源于公司最新宣布的一项重大交易决策。据悉，Ultragenyx将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。这笔交易引发了投资者对Ultragenyx长期收益前景的担忧。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1165015812","title":"异动解读 | Ultragenyx盘前大跌11.83%，4亿美元出售Crysvita特许权使用费引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1165015812","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165015812?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:10","pubTimestamp":1762348250,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc今日盘前大跌11.83%，引发市场广泛关注。这一跌幅主要源于公司最新宣布的一项重大交易决策。据悉，Ultragenyx将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。这笔交易引发了投资者对Ultragenyx长期收益前景的担忧。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1143181614","title":"异动解读 | Ultragenyx夜盘大跌13.68%，4亿美元出售Crysvita特许权使用费引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1143181614","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143181614?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:19","pubTimestamp":1762305557,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc在夜盘交易中股价大幅下跌13.68%，引发市场广泛关注。导致股价下跌的主要原因是公司宣布将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1192009820","title":"异动解读 | Ultragenyx盘后暴跌14.36%，4亿美元出售Crysvita特许权使用费引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1192009820","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192009820?lang=zh_cn&edition=full","pubTime":"2025-11-05 06:47","pubTimestamp":1762296453,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc在盘后交易中股价大幅下跌14.36%，引发市场关注。根据公司公告，Ultragenyx将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。根据协议，OMERS将从2028年1月开始从Crysvita在美国和加拿大的销售中获得额外的特许权使用费份额。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1166002991","title":"Ultragenyx出售Crysvita®（Burosumab）未来北美部分特许权使用费，交易金额为4亿美元，购买方为Omers Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=1166002991","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166002991?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290141,"startTime":"0","endTime":"0","summary":"Ultragenyx出售Crysvita®（Burosumab）未来北美部分特许权使用费，交易金额为4亿美元，购买方为Omers Life Sciences。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1140084792","title":"Ultragenyx Pharmaceutical Inc - Omers将于2028年1月获得Crysvita额外25%的特许权使用费权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1140084792","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140084792?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290131,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc - Omers将于2028年1月获得Crysvita额外25%的特许权使用费权益","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1114807797","title":"Ultragenyx宣布Aurora研究第一位患者接种Gtx-102，评估其他安吉尔曼综合征基因型及年龄组","url":"https://stock-news.laohu8.com/highlight/detail?id=1114807797","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114807797?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:01","pubTimestamp":1761825679,"startTime":"0","endTime":"0","summary":"Ultragenyx宣布Aurora研究第一位患者接种Gtx-102，评估其他安吉尔曼综合征基因型及年龄组","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"1144166983","title":"新闻稿：Ultragenyx根据纳斯达克上市规则5635(c)(4)报告激励授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1144166983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144166983?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:32","pubTimestamp":1761337953,"startTime":"0","endTime":"0","summary":"加利福尼亚州诺瓦托，2025年10月24日-- Ultragenyx Pharmaceutical Inc.，一家专注于稀有和超稀有疾病新疗法开发与商业化的生物制药公司，今天报告了向17名新聘非执行官授予20,317个限制性股票单位。该奖励已获得公司董事会薪酬委员会的批准，并根据Ultragenyx招聘激励计划授予，授予日期为2025年10月16日，作为新员工入职Ultragenyx的激励材料，符合纳斯达克上市规则5635。有关Ultragenyx的更多信息，请访问公司网站：www.ultragenyx.com。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QLD","MNQmain","TQQQ","QQQ","USAW.SI","USJW.SI","RARE","SQQQ","BK4139","PSQ",".IXIC","NVIW.SI","QID","NQmain","TSYW.SI"],"gpt_icon":1},{"id":"1127687038","title":"Ultragenyx公布DTX401 AAV基因疗法治疗糖原储存病Ia型三期研究积极长期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1127687038","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127687038?lang=zh_cn&edition=full","pubTime":"2025-09-09 04:05","pubTimestamp":1757361917,"startTime":"0","endTime":"0","summary":"Ultragenyx公布DTX401 AAV基因疗法治疗糖原储存病Ia型三期研究积极长期数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2558681744","title":"Ultragenyx Pharmaceutical Inc.2025财年第二财季实现净利润-1.15亿美元，同比增加12.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558681744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558681744?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841695,"startTime":"0","endTime":"0","summary":"8月11日，Ultragenyx Pharmaceutical Inc.公布财报，公告显示公司2025财年第二财季净利润为-1.15亿美元，同比增加12.88%；其中营业收入为1.66亿美元，同比增加12.93%，每股基本收益为-1.17美元。机构评级：截至2025年8月11日，当前有21家机构对Ultragenyx Pharmaceutical Inc.目标价做出预测，其中目标均价为84.62美元，其中最低目标价为34.00美元，最高目标价为128.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000348a6de081a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000348a6de081a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ultragenyx.com","stockEarnings":[{"period":"1week","weight":-0.0058},{"period":"1month","weight":0.0465},{"period":"3month","weight":-0.3043},{"period":"6month","weight":-0.1537},{"period":"1year","weight":-0.4454},{"period":"ytd","weight":0.0465}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1437},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化，该产品主要用于治疗罕见和极罕见的疾病，产品最初目标是用于治疗严重的，令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段，该疾病是一种渐进式的肌肉萎缩疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.017448},{"month":2,"riseRate":0.583333,"avgChangeRate":0.072766},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.056113},{"month":4,"riseRate":0.333333,"avgChangeRate":0.004951},{"month":5,"riseRate":0.416667,"avgChangeRate":0.029499},{"month":6,"riseRate":0.75,"avgChangeRate":0.064977},{"month":7,"riseRate":0.416667,"avgChangeRate":0.000441},{"month":8,"riseRate":0.583333,"avgChangeRate":0.035143},{"month":9,"riseRate":0.25,"avgChangeRate":-0.054828},{"month":10,"riseRate":0.25,"avgChangeRate":-0.056376},{"month":11,"riseRate":0.5,"avgChangeRate":0.037007},{"month":12,"riseRate":0.583333,"avgChangeRate":0.015792}],"exchange":"NASDAQ","name":"Ultragenyx Pharmaceutical Inc","nameEN":"Ultragenyx Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultragenyx Pharmaceutical Inc,RARE,Ultragenyx Pharmaceutical Inc股票,Ultragenyx Pharmaceutical Inc股票老虎,Ultragenyx Pharmaceutical Inc股票老虎国际,Ultragenyx Pharmaceutical Inc行情,Ultragenyx Pharmaceutical Inc股票行情,Ultragenyx Pharmaceutical Inc股价,Ultragenyx Pharmaceutical Inc股市,Ultragenyx Pharmaceutical Inc股票价格,Ultragenyx Pharmaceutical Inc股票交易,Ultragenyx Pharmaceutical Inc股票购买,Ultragenyx Pharmaceutical Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}